Relay Therapeutics announced Phase 1/2 ReDiscover trial data for zovegalisib (RLY-2608) 400mg BID fed in combination with fulvestrant in 57 efficacy-evaluable patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer, showing median PFS of 11.1 months and confirmed ORR of 43% among 35 with measurable disease. The regimen was generally well tolerated, consistent with prior data, supporting its use in the ongoing Phase 3 ReDiscover-2 trial.
Key takeaways
Data cut-off January 13, 2026; 60 patients treated with 400mg BID fed zovegalisib + fulvestrant
Efficacy population: 57 patients without PTEN/AKT co-mutation, all prior CDK4/6 and endocrine therapy
Median follow-up 12.0 months; median PFS 11.1 months (95% CI 7.3-13.0)